Title

Cell & Gene Therapies State of the Industry Briefing
Monday
January
09
Download ARM's 2017 Industry Update slides and view the full webcast of the 7th Annual Cell & Gene Therapies State of the Industry Briefing.
San Francisco, CA

Webcast & Industry Update PPT Now Available!
Couldn't attend this year's Cell & Gene Therapies State of the Industry Briefing in-person or looking to have a copy of the slides to reference again? View the full webcast below and download the 2017 Industry Update PPT presentation.

To see all three of the video options click on the horizontal bars in the upper left corner.

Agenda
8:00am - 8:20am | Introduction & Industry Update
Robert Preti, Chairman, Alliance for Regenerative Medicine; President, PCT, A Caladrius Company; SVP, Manufacturing and Technical Operations, Caladrius Biosciences

8:20am – 9:05am | Cell Therapies: Essential Requirements for Near-term and Long-term Commercial Success
This session will address the primary issues cell therapy companies are facing in regards to commercialization and continuing momentum in the sector. Discussion topics will include manufacturing, scale-up, assay development, logistics and market access.
Robert Preti, Chairman, Alliance for Regenerative Medicine; President, PCT, A Caladrius Company; SVP, Manufacturing and Technical Operations, Caladrius Biosciences (moderator)
Thomas Farrell, President and CEO, Bellicum Pharmaceuticals
Manfred Rüdiger, CEO, Kiadis Pharma
Barbra Sasu, VP, Allogeneic CAR T Platform, Pfizer
Jeff Walsh, Chief Financial and Strategy Officer, bluebird bio

9:05am – 9:50am | The Gene Therapy Pipeline: Will Clinical and Regulatory Progress Match Patient and Investor Expectations?
This panel will closely examine the current gene therapy and gene editing pipelines and discuss expectations of technical and clinical progress over the next 3-5 years in the sector's leading disease indications.
Sarah Haecker Meeks, Chief Scientific Officer, Adjuvant Partners; Director, Technology Sections, Alliance for Regenerative Medicine (moderator)
Nessan Bermingham, CEO, President and Founder, Intellia Therapeutics
Chris Mason, Chief Science Officer, AvroBio
Matthew Patterson, President and CEO, Audentes Therapeutics

​9:50am | Program Close

Who Attends?
Over 400 of the cell and gene therapy field's top stakeholders including company founders, C-level business executives, investors, media, patient advocates and academic leaders interested in learning more on the sector's recent advances and outlook for the industry in the coming year.

Event Details
Date: Monday, January 9, 2017

Time: 8:00am - 9:50am
Location:
Parc 55 San Francisco, A Hilton Hotel
55 Cyril Magnin St.
San Francisco, CA 94102

Questions?
Please contact Laura Parsons at lparsons@alliancerm.org.

Held in Conjunction With